Antimicrobial Combination Therapy to Treat Difficult-to-Treat Infections: From Bench to the Bedside
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".
Deadline for manuscript submissions: 15 August 2024 | Viewed by 43257
Special Issue Editors
Interests: biofilm-related infections; antimicrobial resistance; nosocomial infections; anti-biofilm antibiotics
Special Issues, Collections and Topics in MDPI journals
Interests: surgical site infection; prosthetic and foreign-material-related infection; diagnostic microbiology; antimicrobial stewardship
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues，
Antimicrobial combinations have been traditionally used in order to achieve synergy between molecules or for the treatment of difficult-to-treat infections.
In recent years, the combination of new or already known antimicrobial substances (either antibiotics or non-antibiotic therapeutic adjuvants able to increase antibiotic efficacy) has been exploited to overcome the increasing problem of multidrug resistance. In this setting, definite evidence of the optimal indications of combination therapy or its superiority over monotherapy is still lacking, and represents an area of debate.
Several patient and/or disease conditions may lean towards preferring antimicrobial combinations over monotherapy. Furthermore, whether an ideal partner for a combination therapeutic strategy exists is still a matter of debate.
Studies are needed to understand whether combination therapy can be used and show satisfactory efficacy. Clinical microbiology studies and susceptibility tests are needed to investigate in vitro synergisms. Pharmacokinetic/pharmacodynamic (either animal or human) studies are needed to understand whether the target attainment can be reached. Clearly, clinical studies, either observational or randomized control trials, are needed to investigate the efficacy of combination therapy.
In this Special Issue of Antibiotics, we welcome the submission of original research and review articles. Pharmacokinetic/pharmacodynamic studies may also be considered. We welcome fundamental science, animal studies, clinical trials, and observational studies. We are particularly interested in new antibiotics or molecules used to treat multidrug-resistant microorganisms.
Dr. Alessandra Oliva
Dr. Erlangga Yusuf
Dr. Alessandra Mularoni
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- combination treatment
- synergy
- critically ill patients
- difficult-to-treat microorganisms
- fosfomycin
- multi-drug resistance
- multi-drug resistant gram negatives
- sepsis and septic shock
- endocarditis
- methicillin-resistant staphylococcus aureus
- PK/PD
